| 1. | Clinical analysis of plasma exchange for 64 patients with fulminant hepatitis
血浆置换治疗重型肝炎64例临床分析 |
| 2. | Effect of oxymatrine on murine fulminant hepatitis and hepatocyte apoptosis
氧化苦参碱对小鼠暴发型肝炎及肝细胞凋亡作用的研究 |
| 3. | So the prevention and therapy of fulminant hepatitis is still a very important problem
重肝的防治，仍是现今肝病研究的重大课题。 |
| 4. | Result the highest mortality of fulminant hepatitis was among patients with chronic hepatitis b
结果重型肝炎的病死率仍以慢性乙型肝炎为高。 |
| 5. | Objective to evaluate the efficacy and safety of prostaglandin e1 for treatment of chronic fulminant hepatitis
摘要目的评价脂微球载体前列腺素对慢性重型肝炎患者血清甲胎蛋白及其预后的影响。 |
| 6. | Viral hepatitis a rarely leads to signficant necrosis , but hepatitis b can result in a fulminant hepatitis with extensive necrosis
甲肝很少引起显著的坏死，但乙肝能够导致广泛肝细胞坏死的爆发型肝炎。 |
| 7. | Objective to investigate the death causation and complications of fulminant hepatitis and explore measures to improve the survival rate
摘要目的探讨重型肝炎的死亡原因及主要并发症，以进一步提高存活率。 |
| 8. | Conclusion the primary measure to reduce the mortality of fulminant hepatitis is to take precautionary measures to reduce the secondary infections in hepatitis b patients
结论降低重型肝炎的病死率首先做好预防，减少乙型肝炎病人的继发感染。 |
| 9. | Methods 58 cases of chronic fulminant hepatitis patients were randomly divided into the treatment group ( n = 29 ) and the control group ( n = 29 ) to receive prostaglandin e1 for three weeks
方法将58例慢性重型肝炎患者随机、平均分为脂微球载体前列腺素治疗组与对照组，疗程3周。 |
| 10. | The keystone in reducing the mortality of fulminant hepatitis is to avoid the secondary impairment caused by immunopathology and enterogenous endotoxin and take active measures to prevent and treat all complications
早期阻止免疫病理和肠源性内毒素的继发性损伤，积极预防和治疗各种并发症是降低重型肝炎病死率的关键。 |
